CapsoVision Inc（CV）股票分析CVCapsoVision Inc

CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule. It operates in the Healthcare sector.

CapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position and drive future growth. The current price is $6.53, and analysts have set a price target of $9 to $10, indicating a potential upside of 37% to 53%. Additionally, the company reported a 10% revenue growth in Q2 2026, reflecting strong demand for its products. However, the main risk is its negative net income, which stands at -$7,481,000 for Q2 2026, indicating ongoing financial challenges that investors should consider.